Myopic choroidal neovascularisation: Current concepts and update on clinical management

British Journal of Ophthalmology

Volumn 99, Issue 3, 2015, Pages 289-296

  Wong, Tien Y ^a   Ohno Matsui, Kyoko ^b   Leveziel, Nicolas ^c   Holz, Frank G ^d   Lai, Timothy Y ^e   Yu, Hyeong Gon ^f   Lanzetta, Paolo ^g   Chen, Youxin ^h   Tufail, Adnan ⁱ  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c Centre hospitalier Henri Laborit   (France)

^d UNIVERSITY OF BONN   (Germany)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f Seoul National University College of Medicine   (South Korea)

^g SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^h PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

ⁱ MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PLACEBO; RANIBIZUMAB; VERTEPORFIN; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; ATROPHY; BIOMICROSCOPY; CHORIORETINAL ATROPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; LASER COAGULATION; MULTICENTER STUDY (TOPIC); MYOPIA; MYOPIC CHOROIDAL NEOVASCULARISATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW (TOPIC); VISUAL ACUITY; ALGORITHM; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; COMPLICATION; DECISION SUPPORT SYSTEM; MYOPIA, DEGENERATIVE; PHOTOCHEMOTHERAPY;

ALGORITHMS; ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; DECISION SUPPORT TECHNIQUES; HUMANS; LASER COAGULATION; MYOPIA, DEGENERATIVE; PHOTOCHEMOTHERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84923307650     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-305131     Document Type: Article

References (96)

1. Avila MP, Weiter JJ, Jalkh AE, et al. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984;91:1573-81.
2. Fried M, Siebert A, Meyer-Schwickerath G, et al. Natural history of Fuchs' spot: a long-term follow-up study. Doc Ophthal Proc Series 1981;28:215-21.
3. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983;90:923-6.
4. Neelam K, Cheung CM, Ohno-Matsui K, et al. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res 2012;31:495-525.
5. Leveziel N, Yu Y, Reynolds R, et al . Genetic factors for choroidal neovascularization associated with high myopia. Invest Ophthalmol Vis Sci 2012;53:5004-9.
6. Ikuno Y, Jo Y, Hamasaki T, et al. Ocular risk factors for choroidal neovascularization in pathologic myopia. Invest Ophthalmol Vis Sci 2010;51:3721-5.
7. Seko Y, Fujikura H, Pang J, et al. Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro. Invest Ophthalmol Vis Sci 1999;40:3287-91.
8. Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2003;87:570-3.
9. Hayashi K, Ohno-Matsui K, Shimada N, et al. Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology 2010;117:1595-611.
10. Fredrick DR. Myopia. BMJ 2002;324:1195-9.
11. Akagi-Kurashige Y, Kumagai K, Yamashiro K, et al. Vascular endothelial growth factor gene polymorphisms and choroidal neovascularization in highly myopic eyes. Invest Ophthalmol Vis Sci 2012;53:2349-53.
12. Miyake M, Yamashiro K, Nakanishi H, et al. Evaluation of pigment epithelium-derived factor and complement factor I polymorphisms as a cause of choroidal neovascularization in highly myopic eyes. Invest Ophthalmol Vis Sci 2013;54:4208-12.
13. Wakabayashi T, Ikuno Y. Choroidal filling delay in choroidal neovascularisation due to pathological myopia. Br J Ophthalmol 2010;94:611-15.
14. Steidl SM, Pruett RC. Macular complications associated with posterior staphyloma. Am J Ophthalmol 1997;123:181-7.
15. Chan WM, Ohji M, Lai TY, et al . Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol 2005;89:1522-8.
16. Miller DG, Singerman LJ. Natural history of choroidal neovascularization in high myopia. Curr Opin Ophthalmol 2001;12:222-4.
17. Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol 2008;53:121-38.
18. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial -VIP report no. 1. Ophthalmology 2001;108:841-52.
19. Channa R, Ibrahim M, Sepah Y, et al. Characterization of macular lesions in punctate inner choroidopathy with spectral domain optical coherence tomography. J Ophthalmic Inflamm Infect 2012;2:113-20.
20. Vance SK, Khan S, Klancnik JM, et al. Characteristic spectral-domain optical coherence tomography findings of multifocal choroiditis. Retina 2011;31:717-23.
21. Watzke RC, Packer AJ, Folk JC, et al. Punctate inner choroidopathy. Am J Ophthalmol 1984;98:572-84.
22. Silva R. Myopic maculopathy: a review. Ophthalmologica 2012;228:197-213.
23. Wong TY, Ferreira A, Hughes R, et al. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol 2014;157:9-25 e12.
24. Leveziel N, Caillaux V, Bastuji-Garin S, et al. Angiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization. Am J Ophthalmol 2013;155:913-19.
25. Jonas JB, Jonas SB, Jonas RA, et al. Parapapillary atrophy: histological gamma zone and delta zone. PLoS One 2012;7:e47237.
26. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al . Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003;110:1297-305.
27. Kojima A, Ohno-Matsui K, Teramukai S, et al. Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2006;244:1474-9.
28. Yoshida T, Ohno-Matsui K, Ohtake Y, et al. Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 2002;109:712-19.
29. Hayashi K, Ohno-Matsui K, Yoshida T, et al . Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2005;243:13-19.
30. Hotchkiss ML, Fine SL. Pathologic myopia and choroidal neovascularization. Am J Ophthalmol 1981;91:177-83.
31. Tabandeh H, Flynn HW Jr, Scott IU, et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999;106:2063-7.
32. Ruiz-Moreno JM, Montero JA. Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur J Ophthalmol 2002;12:117-22.
33. Tano Y. Pathologic myopia: where are we now? Am J Ophthalmol 2002;134:645-60.
34. Virgili G, Menchini F. Laser photocoagulation for choroidal neovascularisation in pathologic myopia. Cochrane Database Syst Rev 2005:CD004765.
35. Secretan M, Kuhn D, Soubrane G, et al . Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 1997;7:307-16.
36. Altan T, Acar N, Kapran Z, et al. Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors. Int Ophthalmol 2012;32:119-25.
37. Chan WM, Lai TY, Wong AL, et al. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 2007;91:174-9.
38. Chen YS, Lin JY, Tseng SY, et al. Photodynamic therapy for Taiwanese patients with pathologic myopia: a 2-year follow-up. Retina 2007;27:839-45.
39. Costa RA, Williams GA. Twofold illumination photodynamic therapy scheme for subfoveal choroidal neovascularization in pathologic myopia: results from a randomized pilot study. Retina 2006;26:757-64.
40. Hayashi K, Ohno-Matsui K, Shimada N, et al. Long-term results of photodynamic therapy for choroidal neovascularization in Japanese patients with pathologic myopia. Am J Ophthalmol 2011;151:137-47 e1.
41. Hayashi K, Ohno-Matsui K, Teramukai S, et al. Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls. Am J Ophthalmol 2008;145:518-26.
42. Krebs I, Binder S, Stolba U, et al. Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy. Am J Ophthalmol 2005;140:416-25.
43. Lam DS, Chan WM, Liu DT, et al. Photodynamic therapy with vertepor fin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up. Br J Ophthalmol 2004;88:1315-19.
44. Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 2003;87:173-6.
45. Pece A, Isola V, Vadala M, et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study. Retina 2006;26:746-51.
46. Pece A, Milani P, Isola V, et al. A long-term study of photodynamic therapy with verteporfin for choroidal neovascularization at the edge of chorioretinal atrophy in pathologic myopia. Ophthalmologica 2011;225:161-8.
47. Pece A, Vadala M, Isola V, et al. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study. Am J Ophthalmol 2007;143:449-54.
48. Coutinho AM, Silva RM, Nunes SG, et al. Photodynamic therapy in highly myopic eyes with choroidal neovascularization: 5 years of follow-up. Retina 2011;31:1089-94.
49. Giansanti F, Virgili G, Donati MC, et al. Long-term results of photodynamic therapy for subfoveal choroidal neovascularization with pathologic myopia. Retina 2012;32:1547-52.
50. Schnurrbusch UE, Jochmann C, Wiedemann P, et al. Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2005;243:829-33.
51. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Vertepor fin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 2003;110:667-73.
52. Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 2014;121:682-92.
53. Tufail A, Narendran N, Patel PJ, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology 2013;120:1944-5.
54. Tufail A, Patel PJ, Sivaprasad S, et al. Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye (Lond) 2013;27:709-15.
55. OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine. 2011. http://www.cebm.net/index.aspx? o=5653 (accessed 13 Nov 2013).
56. Calvo-Gonzalez C, Reche-Frutos J, Donate J, et al. Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment. Am J Ophthalmol 2011;151:529-34.
57. Franqueira N, Cachulo ML, Pires I, et al. Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab. Ophthalmologica 2012;227:39-44.
58. Lai TY, Luk FO, Lee GK, et al. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond) 2012;26:1004-11.
59. Monés JM, Amselem L, Serrano A, et al. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond) 2009;23:1275-80, quiz 81.
60. Silva RM, Ruiz-Moreno JM, Rosa P, et al. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 2010;30:407-12.
61. Vadala M, Pece A, Cipolla S, et al. Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study. Br J Ophthalmol 2011;95:657-61.
62. Lai TY, Chan WM, Liu DT, et al. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009;29:750-6.
63. Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 2010;30:418-24.
64. Ikuno Y, Sayanagi K, Soga K, et al . Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009;147:94-100 e1.
65. Chan WM, Lai TY, Liu DT, et al. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009;93:150-4.
66. Gharbiya M, Allievi F, Mazzeo L, et al. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009;147:84-93 e1.
67. Ruiz-Moreno JM, Montero JA, Amat-Peral P. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses. Graefes Arch Clin Exp Ophthalmol 2011;249:595-9.
68. Ruiz-Moreno JM, Montero JA, Arias L, et al. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina 2010;30:1609-15.
69. Ruiz-Moreno JM, Lopez-Galvez MI, Donate J, et al. Myopic choroidal neovascularization. Ophthalmology 2011;118:2521-3.
70. Ruiz-Moreno JM, Lopez-Galvez MI, Montero Moreno JA, et al. Intravitreal bevacizumab in myopic neovascular membranes: 24-month results. Ophthalmology 2013;120:1510-11 e1.
71. Iacono P, Parodi MB, Papayannis A, et al. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series. Retina 2011;31:1841-7.
72. Gharbiya M, Cruciani F, Parisi F, et al. Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2012;96:1068-72.
73. Hayashi K, Shimada N, Moriyama M, et al . Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia. Retina 2012;32:687-95.
74. Hayashi K, Ohno-Matsui K, Teramukai S, et al. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 2009;148: 396-408.
75. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-67.
76. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
77. Curtis LH, Hammill BG, Schulman KA, et al. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128:1273-9.
78. Cruess AF, Giacomantonio N. Cardiac issues of noncardiac drugs: the rising story of Avastin in age-related macular degeneration. Ophthalmologica 2014;231:75-9.
79. US Food and Drug Administration. Potential use of Avastin in the treatment of wet age-related macular degeneration. 2011. http://www.fda.gov/Drugs/DrugSafety/ ucm270296.htm (accessed 11 Jul 2013).
80. Nakanishi H, Tsujikawa A, Yodoi Y, et al. Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization. Eye (Lond) 2011;25:375-81.
81. Parodi MB, Iacono P, Papayannis A, et al. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 2010;128:437-42.
82. Yodoi Y, Tsujikawa A, Nakanishi H, et al. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2009;147:816-24, 24 e1.
83. Ruiz-Moreno JM, Arias L, Montero JA, et al. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome. Br J Ophthalmol 2013;97:1447-50.
84. Yang HS, Kim JG, Kim JT, et al. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab. Am J Ophthalmol 2013;156:1201-10 e2.
85. Miyake M, Yamashiro K, Akagi-Kurashige Y, et al. Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia. Ophthalmology 2014;121: 225-33.
86. Gharbiya M, Giustolisi R, Allievi F, et al. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab-a randomized controlled trial. Am J Ophthalmol 2010;149:458-64 e1.
87. Iacono P, Parodi MB, Papayannis A, et al. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina 2012;32:1539-46.
88. ClinicalTrials.gov. VEGF trap-eye in choroidal neovascularization secondary to pathologic myopia (mCNV) (MYRROR). 2012. http://clinicaltrials.gov/ct2/show/ NCT01249664?term=aflibercept+AND+myopia&rank=1 (accessed 1 Jul 2013).
89. Bayer HealthCare. Positive phase 3 results for VEGF Trap-Eye (intravitreal aflibercept) in myopic choroidal neovascularization (mCNV). 2013. http://press.healthcare.bayer. com/en/press/auth/news-details-page.php/15070/2013-0317 (accessed 25 Jul 2013).
90. Wang E, Chen Y. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina 2013;33:1375-92.
91. Novartis. Lucentis summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/ 000715/WC500043546.pdf (accessed 13 Nov 2013).
92. Akiba J. Prevalence of posterior vitreous detachment in high myopia. Ophthalmology 1993;100:1384-8.
93. Kobayashi H, Kobayashi K, Okinami S. Macular hole and myopic refraction. Br J Ophthalmol 2002;86:1269-73.
94. Lewis H. Peripheral retinal degenerations and the risk of retinal detachment. Am J Ophthalmol 2003;136:155-60.
95. Tang J, Rivers MB, Moshfeghi AA, et al . Pathology of macular foveoschisis associated with degenerative myopia. J Ophthalmol 2010;2010:175613.
96. Shimada N, Ohno-Matsui K, Hayashi K, et al. Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization. Jpn J Ophthalmol 2011;55:378-82.